However, for unclear reasons, the rate of classical AML driver mutations (found in approximately 30% of TP53 wild-type cases) is low, with only 2–7% as cases of TP53m-AML-harboring mutations in NPM1 or FLT3 [10,21,23,24,25]. This evidence concerns the gene TP53 and acute myeloid leukemia.